Our research provided a theoretical rationale for the structural optimisation of benzimidazole derivatives as potent FLT3 inhibitors and demonstrated that compound 8r could be a valuable scaffold for AML therapeutics due to its strong inhibitory activity against FLT3 and FLT3 mutants correlated with the secondary resistance mechanism of AML. The gene discussed is FLT3; the disease is acute myeloid leukemia.